title: Severe refractory hidradenitis suppurativa in an HIV-positive patient successfully treated with infliximab.
authors.affiliation: Clinical Immunology Unit, Departments of Immunology, Hospital Universitario Gregorio Marañon, Madrid, Spain.
authors.forename: Diana
authors.initials: D
authors.lastname: Alecsandru
authors.forename: Belén
authors.initials: B
authors.lastname: Padilla
authors.forename: José Antonio Avilés
authors.initials: JA
authors.lastname: Izquierdo
authors.forename: Eduardo
authors.initials: E
authors.lastname: Fernández-Cruz
authors.forename: Silvia
authors.initials: S
authors.lastname: Sánchez-Ramón
mesh_terms: D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D015483:HIV Antibodies / Q000032:analysis; D006679:HIV Seropositivity / Q000150:complications*; D015497:HIV-1 / Q000235:genetics / Q000276:immunology*; D017497:Hidradenitis Suppurativa / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D006801:Humans; D000069285:Infliximab; D008297:Male; D008875:Middle Aged; D012367:RNA, Viral / Q000032:analysis; D012720:Severity of Illness Index; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
chemical_list: D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D015483:HIV Antibodies; D012367:RNA, Viral; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab